Recent Progress on Primary Central Nervous System Lymphoma—From Bench to Bedside

• Main Authors: Liang Shao, Chengshi Xu, Huijing Wu, Muhammad Jamal, Shan Pan, Sirui Li, Fei Chen, Ding Yu, Kui Liu, Yongchang Wei
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-08-01
• Series: Frontiers in Oncology
• Subjects: Primary CNS lymphoma; Bruton’s tyrosine kinase inhibitor; ASCT; CAR T; whole-brain radiotherapy
• Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2021.689843/full

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extra-nodal lymphoma. The high relapse rate of PCNSL remains a major challenge to the hematologists, even though patients exhibit high sensitivity to the methotrexate-based chemotherapeutic regimens. Recently, the advent of Bruton’s tyrosine kinase inhibitor (BTKi) and CAR T treatment has made more treatment options available to a proportion of patients. However, whether BTKi monotherapy should be given alone or in combination with conventional chemotherapy is still a clinical question. The status of CAR T therapy for PCNSLs also needs to be elucidated. In this review, we summarized the latest progress on the epidemiology, pathology, clinical manifestation, diagnosis, and treatment options for PCNSLs.